http://immunostherapeutics.com/  

8952 Schlieren, Wagistrasse 14

 info@immunostherapeutics.com

ImmunOs Therapeutics AG is a clinical-stage biotechnology company developing the next generation of novel immunotherapies that enhance the efficacy of market leading checkpoint inhibitors and costimulatory agonists for cancer therapy. The company is actively discussing and exploring new strategic collaborations with leading global pharmaceutical companies.

http://www.novagotherapeutics.com  

8952 Schlieren, Wagistrasse 27

 info@novagotherapeutics.com

NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics that promote nerve repair and regeneration in the treatment of cerebral stroke and spinal cord injury. NovaGo is developing human antibody therapeutics against Nogo-A. Nogo-A is the most potent inhibitor of nerve fiber regeneration. Anti-NogoA treatment promotes recovery of function in several animal models of stroke. Novago Therapeutics' anti-NogoA treatment represents a novel, regenerative approach for stroke. Recovery of function in stroke and other neurological disorders will be a clinical breakthrough and have a major economic impact on health care.

https://www.repertoire.com/  

8952 Schlieren, Wagistrasse 27

 info@repertoire.com

The key to our strategy lies in understanding the inner workings of the immune synapse – the interaction between the T cell and the antigen presenting cell which dictates the immune code that tells a T cell to become toxic and to kill the infected tissue. Our scientists created and developed the DECODETM and DEPLOY suite of technologies, which allows in-depth characterization of TCR-antigen pairings – and the ability to rationally design and clinically develop targeted immune medicines. Our scientists also have developed novel technologies that attach potent immunomodulators to T cells, enabling us to deliver potent cytokines such as IL-15 or IL-12 directly to tumors by using the natural homing power of the T cells to traffic to diseased tissue.

https://www.pharmabiome.com/  

8952 Schlieren, Wagistrasse 27

PharmaBiome has developed unique technologies to access the entire range of intestinal bacteria for the design and production of function-based consortia at scale.

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18

 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

https://dinamiqs.com/  

8952 Schlieren, Wagistrasse 25

 info@dinamiqs.com

We are a science-driven contract development and manufacturing organization offering end-to-end viral vector manufacturing solutions. We offer customized services for companies and institutions developing innovative genetic medicines. As a science and technology-driven platform, we provide a comprehensive approach to viral vector manufacturing, from lab-scale development to scalable bioreactor implementation, process optimization, formulation, and stringent quality control.

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://kuori.ch/  

8952 Schlieren, Wagistrasse 4

 info@kuori.ch

We started KUORI in 2022. We are an innovative Swiss Cleantech company committed to transitioning to a post-oil economy by transforming consumer plastics through a circular economy approach. As a B2B enterprise, we provide cutting-edge and eco-friendly granules, seamlessly fitting into existing manufacturing processes of diverse sectors including fashion, outdoor equipment and tools. Overall our material has a PCF (Product Carbon Footprint) potentially 60% lower compared to conventional plastics. We leverage food byproducts - such as olive pits and walnut shells - to produce novel bio-based, biodegradable, and elastic materials that have a patent pending. Our materials only produce biodegradable microplastics, directly addressing a critical environmental concern.